FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384704888> ?p ?o ?g. }

• W4384704888 endingPage "1510" @default.
• W4384704888 startingPage "1502" @default.
• W4384704888 abstract "Abstract Background Patients with colorectal peritoneal metastases who are not eligible for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) owing to extensive peritoneal disease have a poor prognosis. It was hypothesized that these patients may benefit from the addition of intraperitoneal irinotecan to standard palliative systemic chemotherapy. Methods This was a classical 3 + 3 phase I dose-escalation trial in patients with colorectal peritoneal metastases who were not eligible for CRS-HIPEC. Intraperitoneal irinotecan was administered every 2 weeks, concomitantly with systemic FOLFOX (5-fluorouracil, folinic acid, oxaliplatin)–bevacizumab. The primary objective was to determine the maximum tolerated dose and dose-limiting toxicities. Secondary objectives were to elucidate the systemic and intraperitoneal pharmacokinetics, safety profile, and efficacy. Results Eighteen patients were treated. No dose-limiting toxicities were observed with 50 mg (4 patients) and 75 mg (9 patients) intraperitoneal irinotecan. Two dose-limiting toxicities occurred with 100 mg irinotecan among five patients. The maximum tolerated dose of intraperitoneal irinotecan was established to be 75 mg, and it was well tolerated. Intraperitoneal exposure to SN-38 (active metabolite of irinotecan) was high compared with systemic exposure (median intraperitoneal area under the curve (AUC) to systemic AUC ratio 4.6). Thirteen patients had a partial radiological response and five had stable disease. Four patients showed a complete response during post-treatment diagnostic laparoscopy. Five patients underwent salvage resection or CRS-HIPEC. Median overall survival was 23.9 months. Conclusion Administration of 75 mg intraperitoneal irinotecan concomitantly with systemic FOLFOX–bevacizumab was safe and well tolerated. Intraperitoneal SN-38 exposure was high and prolonged. As oncological outcomes were promising, intraperitoneal administration of irinotecan may be a good alternative to other, more invasive and costly treatment options. A phase II study is currently accruing." @default.
• W4384704888 created "2023-07-20" @default.
• W4384704888 creator A5003594769 @default.
• W4384704888 creator A5005021982 @default.
• W4384704888 creator A5006155689 @default.
• W4384704888 creator A5013432555 @default.
• W4384704888 creator A5017692892 @default.
• W4384704888 creator A5018004001 @default.
• W4384704888 creator A5019741685 @default.
• W4384704888 creator A5021759589 @default.
• W4384704888 creator A5021833630 @default.
• W4384704888 creator A5022457795 @default.
• W4384704888 creator A5033102166 @default.
• W4384704888 creator A5055194493 @default.
• W4384704888 creator A5065885053 @default.
• W4384704888 creator A5069995065 @default.
• W4384704888 creator A5071697710 @default.
• W4384704888 creator A5072400728 @default.
• W4384704888 creator A5074174053 @default.
• W4384704888 creator A5077655728 @default.
• W4384704888 date "2023-07-19" @default.
• W4384704888 modified "2023-10-12" @default.
• W4384704888 title "Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases" @default.
• W4384704888 cites W1563590460 @default.
• W4384704888 cites W1970179483 @default.
• W4384704888 cites W2004554342 @default.
• W4384704888 cites W2004770693 @default.
• W4384704888 cites W2013887280 @default.
• W4384704888 cites W2033560303 @default.
• W4384704888 cites W2037529039 @default.
• W4384704888 cites W2047702121 @default.
• W4384704888 cites W2060590865 @default.
• W4384704888 cites W2068572207 @default.
• W4384704888 cites W2076554129 @default.
• W4384704888 cites W2090325319 @default.
• W4384704888 cites W2094282118 @default.
• W4384704888 cites W2100446189 @default.
• W4384704888 cites W2128403792 @default.
• W4384704888 cites W2143743735 @default.
• W4384704888 cites W2265162169 @default.
• W4384704888 cites W2316501478 @default.
• W4384704888 cites W2517138562 @default.
• W4384704888 cites W2531203326 @default.
• W4384704888 cites W2547914193 @default.
• W4384704888 cites W2610585226 @default.
• W4384704888 cites W2896913847 @default.
• W4384704888 cites W2992565837 @default.
• W4384704888 cites W3035883604 @default.
• W4384704888 cites W3097193215 @default.
• W4384704888 cites W3106766294 @default.
• W4384704888 cites W3128646645 @default.
• W4384704888 cites W3165521652 @default.
• W4384704888 cites W4206687041 @default.
• W4384704888 cites W4289836879 @default.
• W4384704888 cites W4315754117 @default.
• W4384704888 doi "https://doi.org/10.1093/bjs/znad228" @default.
• W4384704888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37467389" @default.
• W4384704888 hasPublicationYear "2023" @default.
• W4384704888 type Work @default.
• W4384704888 citedByCount "0" @default.
• W4384704888 crossrefType "journal-article" @default.
• W4384704888 hasAuthorship W4384704888A5003594769 @default.
• W4384704888 hasAuthorship W4384704888A5005021982 @default.
• W4384704888 hasAuthorship W4384704888A5006155689 @default.
• W4384704888 hasAuthorship W4384704888A5013432555 @default.
• W4384704888 hasAuthorship W4384704888A5017692892 @default.
• W4384704888 hasAuthorship W4384704888A5018004001 @default.
• W4384704888 hasAuthorship W4384704888A5019741685 @default.
• W4384704888 hasAuthorship W4384704888A5021759589 @default.
• W4384704888 hasAuthorship W4384704888A5021833630 @default.
• W4384704888 hasAuthorship W4384704888A5022457795 @default.
• W4384704888 hasAuthorship W4384704888A5033102166 @default.
• W4384704888 hasAuthorship W4384704888A5055194493 @default.
• W4384704888 hasAuthorship W4384704888A5065885053 @default.
• W4384704888 hasAuthorship W4384704888A5069995065 @default.
• W4384704888 hasAuthorship W4384704888A5071697710 @default.
• W4384704888 hasAuthorship W4384704888A5072400728 @default.
• W4384704888 hasAuthorship W4384704888A5074174053 @default.
• W4384704888 hasAuthorship W4384704888A5077655728 @default.
• W4384704888 hasConcept C121608353 @default.
• W4384704888 hasConcept C126322002 @default.
• W4384704888 hasConcept C141071460 @default.
• W4384704888 hasConcept C143998085 @default.
• W4384704888 hasConcept C2776694085 @default.
• W4384704888 hasConcept C2777802072 @default.
• W4384704888 hasConcept C2778260052 @default.
• W4384704888 hasConcept C2779458272 @default.
• W4384704888 hasConcept C2780259306 @default.
• W4384704888 hasConcept C2780427987 @default.
• W4384704888 hasConcept C2780962732 @default.
• W4384704888 hasConcept C2994223192 @default.
• W4384704888 hasConcept C526805850 @default.
• W4384704888 hasConcept C71924100 @default.
• W4384704888 hasConcept C90924648 @default.
• W4384704888 hasConceptScore W4384704888C121608353 @default.
• W4384704888 hasConceptScore W4384704888C126322002 @default.
• W4384704888 hasConceptScore W4384704888C141071460 @default.
• W4384704888 hasConceptScore W4384704888C143998085 @default.

• next